CV Therapeutics, Inc. [CVTX] Rings the NASDAQ Opening Bell.
February 08, 2008 - CV Therapeutics, Inc. [CVTX]
About this Marketsite Event:
Louis G. Lange M.D., Ph.D, Chairman and Chief Executive Officer of CV Therapeutics, Inc., presides over the opening bell.
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa(r) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases.
Press Inquiries Only:
Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at
jolene.libretto@nasdaq.com. Kindly credit © 2008, The Nasdaq Stock Market, Inc. Reprinted with permission.
Other Photography Inquiries:
For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at
rob.tannenbaum@nasdaq.com.
© Copyright 2008, The NASDAQ Stock Market, Inc.
Reprinted with the permission of The Nasdaq Stock Market, Inc.
